FDA approval means patients with heart failure can benefit from FARXIGA regardless of left ventricular ejection fraction status WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s FARXIGA (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The […]
Tag: Farxiga
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of FARXIGA in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64 million people August 27, 2022 10:36 AM Eastern […]
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del.–(BUSINESS WIRE)–High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or […]
Data from contemporary registry confirms that four out of five patients with heart failure with reduced ejection fraction eligible for treatment with FARXIGA
TRANSLATE-HF study establishes the potential for broad use of the only SGLT2 inhibitor indicated in patients with heart failure with reduced ejection fraction with and without diabetes WILMINGTON, Del.–(BUSINESS WIRE)–New data from a large, contemporary US hospitalized heart failure (HF) registry confirms that four out of five (81.1%) patients with […]
FARXIGA DAPA-CKD Phase III Trial Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal Death in Patients With Chronic Kidney Disease Irrespective of Underlying Cause
Results reinforce FARXIGA’s potential to treat a wide range of patients with chronic kidney disease WILMINGTON, Del.–(BUSINESS WIRE)–A new subgroup analysis from the ground-breaking DAPA-CKD Phase III trial showed that AstraZeneca’s FARXIGA® (dapagliflozin), on top of standard of care, reduced the composite of worsening of kidney function or risk of cardiovascular […]
FARXIGA Approved in the US for the Treatment of Heart Failure in Patients With Heart Failure With Reduced Ejection Fraction
FARXIGA is the first SGLT2 inhibitor proven to significantly reduce the risk of cardiovascular death and hospitalization for heart failure WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s FARXIGA® (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) […]
FARXIGA reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial
New data showed consistent effect of FARXIGA in patients with heart failure with reduced ejection fraction, regardless of background therapy WILMINGTON, Del.–(BUSINESS WIRE)–New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s FARXIGA (dapagliflozin) reduced the incidence of […]
New data from the Phase III DAPA-HF trial showed FARXIGA reduced the worsening of heart failure or cardiovascular death in HFrEF patients with and without chronic kidney disease
AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA® (dapagliflozin) for the treatment of heart failure (HF). The data showed that FARXIGA on top of standard of care reduced the incidence of the primary composite endpoint of cardiovascular (CV) death or worsening of HF […]
FDA Grants Fast Track Designation for FARXIGA in Heart Failure
WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or […]
Detailed results from Phase III DAPA-HF trial showed FARXIGA significantly reduced both the incidence of cardiovascular death and the worsening of heart failure
DAPA-HF is the first outcomes trial with an SGLT2 inhibitor in patients with heart failure with reduced ejection fraction, with and without type 2 diabetes September 1, 2019 – AstraZeneca today announced detailed results from the landmark Phase III DAPA-HF trial that showed FARXIGA (dapagliflozin) on top of standard […]
Recent
Popular
- No commented posts yet